Department of Dermatology, Kosin University College of Medicine, 49267 Busan, Korea.
Acta Derm Venereol. 2020 Feb 29;100(4):adv00069. doi: 10.2340/00015555-3413.
Although low-dose methotrexate (MTX) has been used widely in treatment of a variety of dermatological diseases, including multifocal primary cutaneous anaplastic large cell lymphoma (PCALCL), it has not been established for use in the treatment guidelines for solitary or localized PCALCL. Furthermore, there has been no report of long-term follow-up data in Asian patients with PCALCL treated with low-dose MTX. To investigate the effectiveness and clinical outcome of treatment with low-dose MTX, clinical and long-term follow-up data of 7 patients with solitary or localized PCALCL were analysed retrospectively. Of the 7 patients, 6 (85.7%) showed a complete response and 1 (14.3%) showed partial remission. During follow-up, mean duration of 92.1 months, 5 patients developed one or more cutaneous relapses. At the last follow-up, all of the patients with PCALCL were alive without disease. These results indicate that low-dose MTX is a highly effective and safe treatment for solitary or localized PCALCL as well as multiple relapsed lesions.
虽然低剂量甲氨蝶呤 (MTX) 已广泛用于治疗多种皮肤科疾病，包括多灶性原发性皮肤间变性大细胞淋巴瘤 (PCALCL)，但尚未将其纳入孤立性或局限性 PCALCL 的治疗指南。此外，尚无亚洲患者接受低剂量 MTX 治疗后 PCALCL 的长期随访数据报告。为了研究低剂量 MTX 治疗的有效性和临床结局，回顾性分析了 7 例孤立性或局限性 PCALCL 患者的临床和长期随访数据。7 例患者中，6 例（85.7%）完全缓解，1 例（14.3%）部分缓解。在随访期间，中位时间为 92.1 个月，5 例患者出现 1 次或多次皮肤复发。末次随访时，所有 PCALCL 患者均存活且无疾病。这些结果表明，低剂量 MTX 是治疗孤立性或局限性 PCALCL 以及多发性复发性病变的一种非常有效且安全的治疗方法。
